Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Blue Water Life Science Advisors, LP

Q2 2023 · 13F-HR

Blue Water Life Science Advisors, LPholdings as filed

Filed 2023-08-14 · accession 0001172661-23-003180

$148.2M
Reported value
7
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
632307104NTRANATERA INC$42.9M28.9%881,436CommonSOLE
00974H104AKOYA BIOSCIENCES INC$34.7M23.4%4,697,785CommonSOLE
40131M109GHGUARDANT HEALTH INC$24.2M16.3%676,047CommonSOLE
00650F109ADPTADAPTIVE BIOTECHNOLOGIES COR$20.3M13.7%3,030,434CommonSOLE
63009R109NSTGEURNANOSTRING TECHNOLOGIES INC$11.0M7.45%2,726,891CommonSOLE
57777K106MXCTMAXCYTE INC$8.7M5.84%1,885,000CommonSOLE
835431107SONENDO INC$6.3M4.26%4,643,461CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.